Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway

Dapagliflozin (DAPA), a kind of sodium-glucose cotransporter 2(SGLT2) inhibitor is used to treat diabetes mellitus by inhibiting urine glucose reuptake. Recent clinical outcomes indicate that SGLT2 inhibitors may exert pharmacological activities against non-alcoholic fatty liver diseases. Nonetheles...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2021-09, Vol.907, p.174304, Article 174304
Hauptverfasser:	Luo, Jingyi, Sun, Pengbo, Wang, Yangyang, Chen, Yang, Niu, Yaoyun, Ding, Yipei, Xu, Naihan, Zhang, Yaou, Xie, Weidong
Format:	Artikel
Sprache:	eng
Schlagworte:	AMP-Activated Protein Kinases - metabolism AMPK Animals Benzhydryl Compounds - pharmacology Cell Line Dapagliflozin Diet, High-Fat - adverse effects Fatty Liver - drug therapy Fatty Liver - metabolism Glucosides - pharmacology Glucosides - therapeutic use Hepatic steatosis Humans Lipid Metabolism - drug effects Liver - drug effects Liver - metabolism Liver - pathology Male Mice mTOR NAFLD Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - etiology Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - pathology Oleic Acid - pharmacology Phosphorylation - drug effects Signal Transduction - drug effects Sodium-Glucose Transporter 2 Inhibitors - pharmacology TOR Serine-Threonine Kinases - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!